Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: a pilot study.
OBJECTIVE
Drinking green tea is associated with many health benefits, including increased fat oxidation. We tested the hypothesis that epigallocatechin-3-gallate (EGCG), the main green tea catechin, increases fat oxidation in obese men.


METHODS
Ten healthy overweight/obese males (body mass index 31.3+/-0.8 kg/m(2)) were studied in a randomized, placebo-controlled, double-blind crossover trial. Study supplements were low EGCG (300 mg), high EGCG (600 mg), caffeine (200 mg), EGCG/caffeine (300 mg/200 mg) or placebo and were taken orally for 3 days. At the third day of supplementation, O(2) consumption and CO(2) production was measured by indirect calorimetry to assess energy expenditure and fat oxidation over 4 h each after overnight fasting and after a standardized test meal.


RESULTS
Energy expenditure was not affected by any supplementation, neither after overnight fasting nor after the test meal. During the first 2 h after overnight fasting, fat oxidation increased by 7.7 (not significant, NS), 15.2 (NS), 26.3 (P<0.05 vs placebo) and 35.4% (P<0.01 vs placebo and low EGCG), for low EGCG, high EGCG, caffeine and EGCG/caffeine, respectively. During the first 2 h after the meal, the mean increase in fat oxidation was 33.3 (P<0.05 vs placebo), 20.2 (NS), 34.5 (P<0.05 vs placebo) and 49.4% (P<0.05 vs placebo) for low EGCG, high EGCG, caffeine and EGCG/caffeine, respectively.


CONCLUSIONS
Low EGCG increases postprandial fat oxidation in obese men and this to the same extent as 200 mg caffeine, whereas high EGCG does not exert this effect. Fasting fat oxidation is increased only by caffeine (with or without EGCG). There is no synergism of low EGCG and 200 mg caffeine. Energy expenditure is not affected by EGCG.
Thielecke
F
F
DSM Nutritional Products, Basel, Switzerland.
Rahn
G
G
Böhnke
J
J
Adams
F
F
Birkenfeld
A L
AL
Jordan
J
J
Boschmann
M
M
D000328:Adult; D000975:Antioxidants / Q000494:pharmacology*; D002110:Caffeine / Q000494:pharmacology; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018592:Cross-Over Studies; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004734:Energy Metabolism / Q000187:drug effects; D005215:Fasting; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D009765:Obesity / Q000378:metabolism*; D050177:Overweight / Q000378:metabolism; D010865:Pilot Projects; D010936:Plant Extracts / Q000494:pharmacology*; D019518:Postprandial Period; D055815:Young Adult
D000975:Antioxidants; D010936:Plant Extracts; D002110:Caffeine; D002392:Catechin; C045651:epigallocatechin gallate